Lupin Limited (LUPIN) - Net Assets

Latest as of September 2025: Rs197.28 Billion INR ≈ $2.13 Billion USD

Based on the latest financial reports, Lupin Limited (LUPIN) has net assets worth Rs197.28 Billion INR (≈ $2.13 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs335.00 Billion ≈ $3.62 Billion USD) and total liabilities (Rs137.72 Billion ≈ $1.49 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lupin Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs197.28 Billion
% of Total Assets 58.89%
Annual Growth Rate 19.21%
5-Year Change 24.8%
10-Year Change 54.48%
Growth Volatility 20.34

Lupin Limited - Net Assets Trend (2004–2025)

This chart illustrates how Lupin Limited's net assets have evolved over time, based on quarterly financial data. Also explore Lupin Limited total assets for the complete picture of this company's asset base.

Annual Net Assets for Lupin Limited (2004–2025)

The table below shows the annual net assets of Lupin Limited from 2004 to 2025. For live valuation and market cap data, see Lupin Limited (LUPIN) market capitalisation.

Year Net Assets Change
2025-03-31 Rs172.94 Billion
≈ $1.87 Billion		 +20.32%
2024-03-31 Rs143.73 Billion
≈ $1.55 Billion		 +14.60%
2023-03-31 Rs125.43 Billion
≈ $1.36 Billion		 +2.63%
2022-03-31 Rs122.22 Billion
≈ $1.32 Billion		 -11.81%
2021-03-31 Rs138.58 Billion
≈ $1.50 Billion		 +10.15%
2020-03-31 Rs125.81 Billion
≈ $1.36 Billion		 -8.76%
2019-03-31 Rs137.89 Billion
≈ $1.49 Billion		 +1.26%
2018-03-31 Rs136.17 Billion
≈ $1.47 Billion		 +0.63%
2017-03-31 Rs135.32 Billion
≈ $1.46 Billion		 +20.87%
2016-03-31 Rs111.95 Billion
≈ $1.21 Billion		 +25.82%
2015-03-31 Rs88.98 Billion
≈ $962.30 Million		 +27.14%
2014-03-31 Rs69.99 Billion
≈ $756.86 Million		 +32.96%
2013-03-31 Rs52.64 Billion
≈ $569.24 Million		 +28.85%
2012-03-31 Rs40.85 Billion
≈ $441.80 Million		 +22.58%
2011-03-31 Rs33.33 Billion
≈ $360.41 Million		 +28.51%
2010-03-31 Rs25.93 Billion
≈ $280.46 Million		 +80.21%
2009-03-31 Rs14.39 Billion
≈ $155.63 Million		 +11.63%
2008-03-31 Rs12.89 Billion
≈ $139.41 Million		 +47.61%
2007-03-31 Rs8.73 Billion
≈ $94.45 Million		 +48.30%
2006-03-31 Rs5.89 Billion
≈ $63.68 Million		 +20.04%
2005-03-31 Rs4.91 Billion
≈ $53.05 Million		 +13.67%
2004-03-31 Rs4.32 Billion
≈ $46.67 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Lupin Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 14070570000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings Rs140.71 Billion 81.79%
Common Stock Rs913.20 Million 0.53%
Other Components Rs30.42 Billion 17.68%
Total Equity Rs172.03 Billion 100.00%

Lupin Limited Competitors by Market Cap

The table below lists competitors of Lupin Limited ranked by their market capitalization.

Company Market Cap
Mowi ASA
OL:MOWI
 $11.40 Billion
Stanley Black & Decker Inc
NYSE:SWK
 $11.40 Billion
Healthpeak Properties Inc
NYSE:DOC
 $11.41 Billion
Washington H Soul Pattinson & Company Ltd
AU:SOL
 $11.44 Billion
Metso Oyj
HE:METSO
 $11.39 Billion
China Development Financial Holding Corp
TW:2883
 $11.38 Billion
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
 $11.38 Billion
BorgWarner Inc
NYSE:BWA
 $11.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Lupin Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 142,902,900,000 to 172,035,000,000, a change of 29,132,100,000 (20.4%).
  • Net income of 32,816,200,000 contributed positively to equity growth.
  • Dividend payments of 3,653,100,000 reduced retained earnings.
  • Share repurchases of 398,600,000 reduced equity.
  • New share issuances of 398,600,000 increased equity.
  • Other comprehensive income decreased equity by 141,991,500,000.
  • Other factors increased equity by 141,960,500,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Rs32.82 Billion +19.08%
Dividends Paid Rs3.65 Billion -2.12%
Share Repurchases Rs398.60 Million -0.23%
Share Issuances Rs398.60 Million +0.23%
Other Comprehensive Income Rs-141.99 Billion -82.54%
Other Changes Rs141.96 Billion +82.52%
Total Change Rs- 20.39%

Book Value vs Market Value Analysis

This analysis compares Lupin Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.13x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 214.81x to 6.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-03-31 Rs10.73 Rs2305.20 x
2005-03-31 Rs12.18 Rs2305.20 x
2006-03-31 Rs15.49 Rs2305.20 x
2007-03-31 Rs21.65 Rs2305.20 x
2008-03-31 Rs31.21 Rs2305.20 x
2009-03-31 Rs34.22 Rs2305.20 x
2010-03-31 Rs58.63 Rs2305.20 x
2011-03-31 Rs73.21 Rs2305.20 x
2012-03-31 Rs89.52 Rs2305.20 x
2013-03-31 Rs115.88 Rs2305.20 x
2014-03-31 Rs153.45 Rs2305.20 x
2015-03-31 Rs196.45 Rs2305.20 x
2016-03-31 Rs246.55 Rs2305.20 x
2017-03-31 Rs297.98 Rs2305.20 x
2018-03-31 Rs299.50 Rs2305.20 x
2019-03-31 Rs302.61 Rs2305.20 x
2020-03-31 Rs276.92 Rs2305.20 x
2021-03-31 Rs303.21 Rs2305.20 x
2022-03-31 Rs267.67 Rs2305.20 x
2023-03-31 Rs272.78 Rs2305.20 x
2024-03-31 Rs312.54 Rs2305.20 x
2025-03-31 Rs375.81 Rs2305.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Lupin Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 19.08%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 14.45%
  • • Asset Turnover: 0.78x
  • • Equity Multiplier: 1.70x
  • Recent ROE (19.08%) is above the historical average (19.01%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 32.34% 11.46% 0.99x 2.86x Rs962.34 Million
2005 18.77% 7.28% 0.93x 2.77x Rs429.02 Million
2006 27.75% 10.20% 0.84x 3.22x Rs1.11 Billion
2007 35.33% 15.32% 0.89x 2.59x Rs2.21 Billion
2008 31.90% 15.08% 0.80x 2.63x Rs2.80 Billion
2009 35.20% 13.28% 0.91x 2.90x Rs3.59 Billion
2010 26.54% 14.28% 0.94x 1.98x Rs4.25 Billion
2011 26.29% 15.11% 0.93x 1.87x Rs5.34 Billion
2012 21.62% 12.25% 0.89x 1.99x Rs4.66 Billion
2013 25.25% 13.63% 1.08x 1.71x Rs7.94 Billion
2014 34.67% 18.82% 1.25x 1.47x Rs17.10 Billion
2015 27.08% 18.82% 0.97x 1.48x Rs15.16 Billion
2016 20.25% 16.00% 0.62x 2.03x Rs11.44 Billion
2017 18.95% 14.73% 0.65x 1.97x Rs12.08 Billion
2018 1.85% 1.59% 0.60x 1.94x Rs-11.06 Billion
2019 4.41% 4.14% 0.52x 2.03x Rs-7.68 Billion
2020 -2.15% -1.75% 0.62x 1.99x Rs-15.23 Billion
2021 8.81% 8.02% 0.64x 1.71x Rs-1.64 Billion
2022 -12.57% -9.31% 0.75x 1.80x Rs-27.43 Billion
2023 3.45% 2.58% 0.72x 1.84x Rs-8.16 Billion
2024 13.40% 9.57% 0.83x 1.68x Rs4.85 Billion
2025 19.08% 14.45% 0.78x 1.70x Rs15.61 Billion

Industry Comparison

This section compares Lupin Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $23,713,303,062
  • Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Lupin Limited (LUPIN) Rs197.28 Billion 32.34% 0.70x $11.39 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $988.60 Million 6.59% 1.36x $27.93 Million
Aarti Drugs Limited (AARTIDRUGS) $6.52 Billion 21.67% 1.42x $371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM) $19.90 Billion 13.69% 0.46x $725.68 Million
Abbott India Limited (ABBOTINDIA) $36.99 Billion 32.48% 0.40x $5.85 Billion
Ajanta Pharma Limited (AJANTPHARM) $1.16 Billion 12.69% 1.32x $3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS) $6.25 Billion -40.39% 3.91x $906.19 Million
Alkem Laboratories Limited (ALKEM) $88.47 Billion 18.60% 0.59x $6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN) $1.46 Billion 16.82% 0.29x $178.52 Million
Alembic Pharmaceuticals Limited (APLLTD) $51.90 Billion 11.24% 0.50x $1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA) $23.50 Billion -5.26% 1.65x $8.73 Billion

About Lupin Limited

NSE:LUPIN India Drug Manufacturers - Specialty & Generic
Market Cap
$11.39 Billion
Rs1.05 Trillion INR
Market Cap Rank
#2022 Global
#80 in India
Share Price
Rs2305.20
Change (1 day)
-0.27%
52-Week Range
Rs1851.80 - Rs2357.30
All Time High
Rs2396.10
Categories
Companies in India Drug Manufacturers - Specialty & Generic
About

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more